Dyne Therapeutics (DYN) Set to Announce Quarterly Earnings on Wednesday

Dyne Therapeutics (NASDAQ:DYN) is expected to be releasing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.9073) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 3:00 PM ET.

Dyne Therapeutics Stock Up 3.7%

DYN stock opened at $17.30 on Tuesday. The company has a market cap of $3.23 billion, a PE ratio of -5.20 and a beta of 1.12. The business has a 50-day simple moving average of $18.36 and a 200 day simple moving average of $19.31. Dyne Therapeutics has a 52 week low of $14.00 and a 52 week high of $27.31. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on DYN shares. Oppenheimer downgraded shares of Dyne Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $40.00 to $15.00 in a research note on Wednesday, October 28th. Stifel Nicolaus set a $37.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, September 30th. HC Wainwright cut their price target on shares of Dyne Therapeutics from $50.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, September 30th. Chardan Capital reaffirmed a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $31.29.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 2,160,516 shares of Dyne Therapeutics stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $25.00, for a total value of $54,012,900.00. Following the transaction, the director owned 428,946 shares in the company, valued at $10,723,650. The trade was a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Cox sold 5,658 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total value of $106,823.04. Following the transaction, the chief executive officer directly owned 357,507 shares of the company’s stock, valued at approximately $6,749,732.16. The trade was a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 2,598,706 shares of company stock valued at $65,432,671 in the last quarter. Corporate insiders own 9.46% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for serious muscle diseases. The company’s research is centered on conditions in which the delivery of therapeutic molecules to skeletal muscle and other tissues is a significant challenge.

Dyne uses its proprietary FORCE platform to design targeted therapies intended to improve the delivery of oligonucleotides into muscle cells. The platform incorporates antibodies that bind to the transferrin receptor, which can help transport genetic medicines across cell membranes and into muscle tissue.

Dyne’s pipeline includes DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.